RespireRx Pharmaceuticals Inc. to Present at BIO CEO & Investor Conference 2017
CEO to review dronabinol, a Phase 3-ready medicine for the treatment of obstructive sleep apnea, and provide pipeline update Glen Rock, N.J., Feb. 10, 2017/Globe Newswire – RespireRx Pharmaceuticals Inc. (OTC QB: RSPI) (“RespireRx” or the “Company”), a leader in the development of medicines for the treatment of respiratory disorders for which there are no…
RespireRx Pharmaceuticals Inc. to Present at 9th Annual Biotech Showcase™ 2017
CEO to Review Completed Phase 2B Dronabinol Clinical Trial for the Treatment of Obstructive Sleep Apnea and Provide Pipeline Update Glen Rock, N.J., Jan. 6, 2017/Globe Newswire – RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) (“RespireRx” or the “Company”), a leader in the development of medicines for the treatment of respiratory disorders, particularly sleep apneas and drug-induced…